
|Articles|November 5, 2012
FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE
FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Q&A: The Initiative Bringing Clinical Pharmacy Care to Underserved Patients’ Homes
2
Pharmacists Reimagine the Future of Pharmacy
3
Investigators Link Maternal Distress With Neurodevelopmental Delay Among Children
4
Is it Safe for Birth Control Users to Go Years Without a Period?
5




















































































































































